Gary Nabors - Appili Therapeutics Chief Officer
| APLI Stock | CAD 0.04 0.00 0.00% |
Executive
Gary Nabors is Chief Officer of Appili Therapeutics
| Address | #21-1344 Summer Street, Halifax, NS, Canada, B3H 0A8 |
| Phone | 902 442 4655 |
| Web | https://appilitherapeutics.com |
Appili Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.4422) % which means that it has lost $2.4422 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (9.3872) %, meaning that it generated substantial loss on money invested by shareholders. Appili Therapeutics' management efficiency ratios could be used to measure how well Appili Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Appili Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 8th of January 2025, Return On Equity is likely to grow to 0.45, while Return On Tangible Assets are likely to drop (3.06). At this time, Appili Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 8th of January 2025, Other Current Assets is likely to grow to about 231.3 K, while Total Assets are likely to drop about 1.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mike Lister | JPMorgan Chase Co | N/A | |
| John Deaton | HOME DEPOT CDR | 50 | |
| Donna Morris | Walmart Inc CDR | 56 | |
| David Zapolsky | Amazon CDR | 60 | |
| David Sherwood | Costco Wholesale Corp | N/A | |
| Haydn Chilcott | HOME DEPOT CDR | N/A | |
| Sripada Shivananda | JPMorgan Chase Co | 52 | |
| Molly Battin | HOME DEPOT CDR | N/A | |
| Matthew Carey | HOME DEPOT CDR | 60 | |
| Eduardo Salgado | Brookfield | N/A | |
| Stephanie Wissink | Walmart Inc CDR | N/A | |
| Kathleen Gutmann | UPS CDR | 56 | |
| Tony Maggiore | JPMorgan Chase Co | N/A | |
| Scott Bomar | HOME DEPOT CDR | 51 | |
| Bernard Meyerson | International Business Machines | N/A | |
| Craig Laurie | Brookfield | 52 | |
| Dario Gil | International Business Machines | N/A | |
| Anne Robinson | International Business Machines | N/A | |
| Nando Cesarone | UPS CDR | 53 | |
| David JD | Amazon CDR | 61 | |
| Matthew Guffey | UPS CDR | 45 | |
Management Performance
| Return On Equity | -9.39 | ||||
| Return On Asset | -2.44 |
Appili Therapeutics Leadership Team
Elected by the shareholders, the Appili Therapeutics' board of directors comprises two types of representatives: Appili Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Appili. The board's role is to monitor Appili Therapeutics' management team and ensure that shareholders' interests are well served. Appili Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Appili Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cilla MBA, Pres CEO | ||
| MS MD, Chief Officer | ||
| Arthur Baran, Director Development | ||
| Carl Gelhaus, Director Research | ||
| Kenneth Howling, Acting Officer | ||
| Gary Nabors, Chief Officer |
Appili Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Appili Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.39 | ||||
| Return On Asset | -2.44 | ||||
| Operating Margin | (10.40) % | ||||
| Current Valuation | 14 M | ||||
| Shares Outstanding | 121.27 M | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 11.84 % | ||||
| Number Of Shares Shorted | 1.87 K | ||||
| Price To Book | 1.40 X | ||||
| Price To Sales | 5.13 X |
Pair Trading with Appili Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Appili Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Appili Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Appili Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Appili Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Appili Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Appili Therapeutics to buy it.
The correlation of Appili Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Appili Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Appili Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Appili Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Appili Stock
Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.